HARTE-HANKS INC (HHS) Stock Fundamental Analysis
USA - NASDAQ:HHS - US4161962026 - Common Stock
2.92 USD
-0.09 (-2.99%)
Overall HHS gets a fundamental rating of 3 out of 10. We evaluated HHS against 95 industry peers in the Media industry. HHS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HHS is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
HHS had negative earnings in the past year.
HHS had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: HHS reported negative net income in multiple years.
In multiple years HHS reported negative operating cash flow during the last 5 years.
1.2 Ratios
HHS's Return On Assets of -3.18% is in line compared to the rest of the industry. HHS outperforms 45.26% of its industry peers.
HHS has a Return On Equity (-13.57%) which is in line with its industry peers.
The Return On Invested Capital of HHS (6.95%) is better than 73.68% of its industry peers.
HHS had an Average Return On Invested Capital over the past 3 years of 11.42%. This is above the industry average of 8.55%.
The last Return On Invested Capital (6.95%) for HHS is well below the 3 year average (11.42%), which needs to be investigated, but indicates that HHS had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.18% | ||
| ROE | -13.57% | ||
| ROIC | 6.95% |
ROA(3y)-0.52%
ROA(5y)1.66%
ROE(3y)13.57%
ROE(5y)N/A
ROIC(3y)11.42%
ROIC(5y)N/A
1.3 Margins
With a Operating Margin value of 3.21%, HHS perfoms like the industry average, outperforming 49.47% of the companies in the same industry.
In the last couple of years the Operating Margin of HHS has declined.
HHS's Gross Margin of 18.54% is on the low side compared to the rest of the industry. HHS is outperformed by 73.68% of its industry peers.
In the last couple of years the Gross Margin of HHS has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.21% | ||
| PM (TTM) | N/A | ||
| GM | 18.54% |
OM growth 3Y-16.84%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y15.62%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), HHS is creating some value.
Compared to 1 year ago, HHS has more shares outstanding
HHS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, HHS has a worse debt to assets ratio.
2.2 Solvency
HHS has an Altman-Z score of 14.45. This indicates that HHS is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 14.45, HHS belongs to the best of the industry, outperforming 97.89% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that HHS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.02, HHS belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 14.45 |
ROIC/WACC0.8
WACC8.68%
2.3 Liquidity
A Current Ratio of 1.60 indicates that HHS should not have too much problems paying its short term obligations.
With a decent Current ratio value of 1.60, HHS is doing good in the industry, outperforming 67.37% of the companies in the same industry.
A Quick Ratio of 1.60 indicates that HHS should not have too much problems paying its short term obligations.
HHS has a better Quick ratio (1.60) than 67.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 89.87% over the past year.
The Revenue has decreased by -6.48% in the past year.
Measured over the past years, HHS shows a decrease in Revenue. The Revenue has been decreasing by -3.17% on average per year.
EPS 1Y (TTM)89.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.55%
Revenue 1Y (TTM)-6.48%
Revenue growth 3Y-1.63%
Revenue growth 5Y-3.17%
Sales Q2Q%-14.22%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y131.2%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
HHS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 2.70 indicates a rather cheap valuation of HHS.
Based on the Price/Forward Earnings ratio, HHS is valued cheaper than 96.84% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.27. HHS is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 2.7 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HHS is valued cheaply inside the industry as 95.79% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.81 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for HHS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:HHS (11/4/2025, 8:00:02 PM)
2.92
-0.09 (-2.99%)
Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)
Earnings (Next)
Inst Owners31.88%
Inst Owner Change0%
Ins Owners38.17%
Ins Owner Change1.8%
Market Cap21.64M
Revenue(TTM)174.95M
Net Income(TTM)-3019000
Analysts80
Price TargetN/A
Short Float %0.3%
Short Ratio0.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 2.7 | ||
| P/S | 0.12 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.97 | ||
| P/tB | 1.01 | ||
| EV/EBITDA | 1.81 |
EPS(TTM)-0.41
EYN/A
EPS(NY)1.08
Fwd EY37.01%
FCF(TTM)-1
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS23.61
BVpS3
TBVpS2.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.18% | ||
| ROE | -13.57% | ||
| ROCE | 8.8% | ||
| ROIC | 6.95% | ||
| ROICexc | 7.51% | ||
| ROICexgc | 7.61% | ||
| OM | 3.21% | ||
| PM (TTM) | N/A | ||
| GM | 18.54% | ||
| FCFM | N/A |
ROA(3y)-0.52%
ROA(5y)1.66%
ROE(3y)13.57%
ROE(5y)N/A
ROIC(3y)11.42%
ROIC(5y)N/A
ROICexc(3y)13.82%
ROICexc(5y)N/A
ROICexgc(3y)14.26%
ROICexgc(5y)N/A
ROCE(3y)14.46%
ROCE(5y)N/A
ROICexgc growth 3Y-19.31%
ROICexgc growth 5YN/A
ROICexc growth 3Y-19.72%
ROICexc growth 5YN/A
OM growth 3Y-16.84%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y15.62%
F-Score4
Asset Turnover1.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.05 | ||
| Cap/Depr | 64.48% | ||
| Cap/Sales | 1.64% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 | ||
| Altman-Z | 14.45 |
F-Score4
WACC8.68%
ROIC/WACC0.8
Cap/Depr(3y)122.2%
Cap/Depr(5y)111.4%
Cap/Sales(3y)2.1%
Cap/Sales(5y)1.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.55%
EPS Next Y131.2%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.48%
Revenue growth 3Y-1.63%
Revenue growth 5Y-3.17%
Sales Q2Q%-14.22%
Revenue Next Year4.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-39.85%
EBIT growth 3Y-18.2%
EBIT growth 5YN/A
EBIT Next Year198.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-137.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-119.45%
OCF growth 3YN/A
OCF growth 5YN/A
HARTE-HANKS INC / HHS FAQ
What is the ChartMill fundamental rating of HARTE-HANKS INC (HHS) stock?
ChartMill assigns a fundamental rating of 3 / 10 to HHS.
What is the valuation status of HARTE-HANKS INC (HHS) stock?
ChartMill assigns a valuation rating of 4 / 10 to HARTE-HANKS INC (HHS). This can be considered as Fairly Valued.
What is the profitability of HHS stock?
HARTE-HANKS INC (HHS) has a profitability rating of 3 / 10.
What is the earnings growth outlook for HARTE-HANKS INC?
The Earnings per Share (EPS) of HARTE-HANKS INC (HHS) is expected to grow by 131.2% in the next year.
Is the dividend of HARTE-HANKS INC sustainable?
The dividend rating of HARTE-HANKS INC (HHS) is 0 / 10 and the dividend payout ratio is 0%.